Name
Cochlear North America
What We Do
Cochlear is the global leader in implantable hearing solutions providing cochlear implants and bone
conduction implants.
For more than 40 years, Cochlear has been connecting people all over the globe to the world of sound.
Inspired by his father's struggles, Professor Graeme Clark developed the world’s first multi-channel cochlear
implant to help treat hearing loss. Since then, Cochlear has helped more than 750,000 people of all ages to
hear.
Cochlear continuously strives to develop new technologies and innovations for all recipients – whether they received their implant today or many years ago. Participating in over 100 collaborative research programs
worldwide, Cochlear has invested more than AUD$3 billion in research and development to date.
Cochlear aims to support cochlear implantation becoming the standard of care for people with severe to
profound hearing loss, and offers bone conduction solutions for conductive hearing loss, mixed hearing loss
and single-sided deafness.
Cochlear commenced operations in 1981 as part of the Nucleus Group, and listed on the Australian
Securities Exchange (ASX) in 1995. Cochlear is a Top 50 ASX-listed company with annual global revenues of
around AUD$2 billion.
Cochlear’s global headquarters are on the campus of Macquarie University in Sydney, Australia with regional
headquarters in Asia-Pacific, Europe and the Americas. With a significant international footprint, Cochlear
sells its products in over 180 countries and has a global workforce of more than 5,500 employees based in
over 50 countries.
Cochlear strives to help people hear – aiming to provide them with a lifetime of hearing through the best
possible support.
Hear now. And always
conduction implants.
For more than 40 years, Cochlear has been connecting people all over the globe to the world of sound.
Inspired by his father's struggles, Professor Graeme Clark developed the world’s first multi-channel cochlear
implant to help treat hearing loss. Since then, Cochlear has helped more than 750,000 people of all ages to
hear.
Cochlear continuously strives to develop new technologies and innovations for all recipients – whether they received their implant today or many years ago. Participating in over 100 collaborative research programs
worldwide, Cochlear has invested more than AUD$3 billion in research and development to date.
Cochlear aims to support cochlear implantation becoming the standard of care for people with severe to
profound hearing loss, and offers bone conduction solutions for conductive hearing loss, mixed hearing loss
and single-sided deafness.
Cochlear commenced operations in 1981 as part of the Nucleus Group, and listed on the Australian
Securities Exchange (ASX) in 1995. Cochlear is a Top 50 ASX-listed company with annual global revenues of
around AUD$2 billion.
Cochlear’s global headquarters are on the campus of Macquarie University in Sydney, Australia with regional
headquarters in Asia-Pacific, Europe and the Americas. With a significant international footprint, Cochlear
sells its products in over 180 countries and has a global workforce of more than 5,500 employees based in
over 50 countries.
Cochlear strives to help people hear – aiming to provide them with a lifetime of hearing through the best
possible support.
Hear now. And always
Website
Categories
Implantable Devices, Manufacturing
Phone
+1.303.264-2124
Address
10350 Park Meadows Dr
Lone Tree, CO 80124
United States
Lone Tree, CO 80124
United States
Facebook
Twitter